VEA
CPRX

Virtus ETF Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Virtus ETF Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361K Hold
14,572
– – 0.17% 155
2025
Q4 		$340K Hold
14,572
– – 0.16% 157
2025
Q3 		$287K Sell
14,572
-8,232
-36% -$169K 0.16% 174
2025
Q2 		$495K Hold
22,804
– – 0.3% 95
2025
Q1 		$553K Buy
+22,804
New +$514K 0.36% 83

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Virtus ETF Advisers's CPRX Position: Q1 2026 in Review

Virtus ETF Advisers held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 14,572 shares worth $361K. The position accounts for 0.17% of the portfolio, ranked #155.

Virtus ETF Advisers first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $553K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Virtus ETF Advisers held 14,572 shares of Catalyst Pharmaceutical worth $361K as of Q1 2026.
  • Virtus ETF Advisers left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up 0.17% of Virtus ETF Advisers's portfolio in Q1 2026, its #155 holding.
  • Virtus ETF Advisers first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Virtus ETF Advisers's Catalyst Pharmaceutical position peaked at $553K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.